US Patent

US8628759 — Soft anticholinergic esters

Method of Use · Assigned to Bodor Laboratories Inc · Expires 2026-11-13 · 0y remaining

Vulnerability score 93/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a class of compounds known as soft anticholinergic esters with specific chemical formulas.

USPTO Abstract

Soft anticholinergic esters of the formulas: wherein R 1 and R 2 are both phenyl or one of R 1 and R 2 is phenyl and the other is cyclopentyl; R is C 1 -C 8 alkyl, straight or branched chain; and X â is an anion with a single negative charge; and wherein each asterisk marks a chiral center; said compound having the R, S or RS stereoisomeric configuration at each chiral center unless specified otherwise, or being a mixture thereof.

Drugs covered by this patent

Ecclock (SOFPIRONIUM BROMIDE) · Kaken Pharmaceutical

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2398`	—	Ecclock

Patent Metadata

Patent number: US8628759
Jurisdiction: US
Classification: Method of Use
Expires: 2026-11-13
Drug substance claim: No
Drug product claim: No
Assignee: Bodor Laboratories Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.